After a review of Portage Biotech Inc. (NasdaqCM:PRTG)'s funding requirements, the Board of Directors has made the decision to pause further drug development in the PORT-2 iNKT program. "This was a difficult decision considering the promising phase 1 safety and translational data from the non-small cell lung and melanoma trial," said Dr. Ian B. Walters, chairman and CEO, "As a result, the company will evaluate a range of potential strategic options which may include among other things, finding a partner for our iNKT program or other corporate transactions".
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.179 USD | -0.50% |
|
+18.54% | -90.16% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-90.16% | 3.56M | |
+22.10% | 47.07B | |
+46.45% | 42.06B | |
-3.12% | 39.98B | |
+36.10% | 33.02B | |
-6.30% | 27.9B | |
+18.71% | 27.63B | |
+46.15% | 14.37B | |
+44.52% | 13.45B | |
+0.19% | 12.03B |
- Stock Market
- Equities
- PRTG Stock
- News Portage Biotech Inc.
- Portage Biotech to Evaluate Range of Strategic Options